Philips Proposes Reappointment of Roy Jakobs as CEO
Royal Philips has announced the convening of its 2026 General Shareholders' Meeting (AGM), with an agenda that includes several nomination and reappointment proposals within its governance bodies. The meeting is scheduled for May 8, 2026, in Amsterdam.
The General Meeting will review several proposals concerning the composition of the Supervisory Board and the Board of Management. Philips proposes the appointment of John DeFord as a new member of the Supervisory Board effective from May 8, 2026. The company also proposes the reappointment of three members: Paul Stoffels, Herna Verhagen, and Sanjay Poonen, as well as the reappointment of Roy Jakobs as Chairman/CEO and Chairman of the Board of Management. The agenda also includes a proposal for a remuneration policy for the Supervisory Board.
Standard Agenda Items and Financial Matters
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
In addition to governance issues, the assembly will review standard items: the adoption of the financial statements for the fiscal year 2025, approval of the 2025 remuneration report (advisory vote), and proposals concerning the distribution of dividends in cash or shares. The General Meeting will take place on Friday, May 8, 2026, at 10:00 AM CET at the Okura Hotel Amsterdam. The full agenda and relevant documents have been published in accordance with regulations.
SectorSanté · Technologie · Dispositifs médicaux›Équipements Médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 3.9MD€
Free cash flow: 28M€
Guidance from the release
Nous avons délivré un bon départ en 2026.
Bonne performance au T1, croissance des ventes et des marges.
Risks mentioned
Impact des tarifs et inflation des coûts sur les marges.
Environnement macroéconomique incertain impactant les performances.
Opportunities identified
Croissance des ventes comparables de 4% dans tous les segments.
Augmentation du carnet de commandes grâce à des innovations.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
